

Department of Planning and Budget

2023 Fiscal Impact Statement

1. Bill Number: HB2274

House of Origin	<input checked="" type="checkbox"/> Introduced	<input type="checkbox"/> Substitute	<input type="checkbox"/> Engrossed
Second House	<input type="checkbox"/> In Committee	<input type="checkbox"/> Substitute	<input type="checkbox"/> Enrolled

2. Patron: Kilgore

3. Committee: Health, Welfare and Institutions

4. Title: Pharmacist scope of practice; initiation of treatment for certain diseases and conditions.

5. Summary: Allows pharmacists to initiate treatment with, dispense, or administer controlled substances or devices for the initiation of treatment of group A streptococcus bacteria infection, influenza virus infection, respiratory syncytial virus (RSV) infection, COVID-19 virus infection, and urinary tract infection to persons 18 years of age or older with whom the pharmacist has a bona fide pharmacist-patient relationship in accordance with regulations set forth by the Board of Pharmacy. The bill directs the Board of Medicine, in collaboration with the Board of Pharmacy and the Department of Health, to establish a statewide protocol for the initiation of treatment with and dispensing and administering of drugs and devices by pharmacists in accordance with the provisions of the bill by November 1, 2023, and directs the Board of Pharmacy to adopt emergency regulations to implement the provisions of the bill.

6. Budget Amendment Necessary: No.

7. Fiscal Impact Estimates: Final.

8. Fiscal Implications: This legislation, as amended, would not have a fiscal impact on the Virginia Department of Health or the Department of Health Professions.

9. Specific Agency or Political Subdivisions Affected: None.

10. Technical Amendment Necessary: No.

11. Other Comments: None.